Putting the brakes on angiogenesis through a novel VEGF-KLH (kinoid) vaccine

Expert Review of Vaccines

Volumn 6, Issue 4, 2007, Pages 491-496

  Nair, Jayakumar R ^a   Bansal, Sanjay ^a   Lee, Kelvin P ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Bevacizumab; Immunotherapy; Kinoid; Metastasis; VEGF KLH

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CYTOTOXIC AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN KINOID VACCINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 34548037645     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.4.491     Document Type: Article

References (27)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
2. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6(4), 273-286 (2007).
3. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angogenesis. Nature 359(29), 843-845 (1992).
4. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845-848 (1992). • Identified VEGF as a potential regulator of tumor angiogenesis in human glioblastoma cells.
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 407(6801), 249-257 (2000).
6. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur. J Cancer. 32A, 2451-2460 (1996).
7. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol. Med. 13(6), 223-230 (2007).
8. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3(1), 24-40 (2006).
9. Kim KJ, Li B, Winer J, Armanini M et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423), 841-4 (1993). • Describes use of anti-VEGF monoclonal antibodies to inhibit VEGF-mediated tumor progression in mice.
10. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599 (1997). • First description of the design and efficacy of a humanized anti-VEGF antibody (based on [9]) later commercialized as Avastin® (bevacizumab).
11. Fox WD, Higgins B, Maiese KM et al. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin. Cancer Res. 8, 3226-3231 (2002).
12. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am. J. Pathol. 161, 1917-1924 (2002). • Describes the synergistic effect of bevacizumab with paclitaxel against tumorigenesis.
13. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr. Med. Chem. 13(16), 1845-1857 (2006).
14. Okaji Y, Tsuno NH, Saito S et al. Vaccines targeting tumour angiogenesis - a novel strategy for cancer immunotherapy. Eur. J. Surg. Oncol. 32(4), 363-370 (2006).
15. Rad FH, Buanec HL, Paturance S et al. VEGF-kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc. Natl Acad. Sci. USA 104(8), 2837-2842 (2007).
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000).
17. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29, 10-14 (2002).
18. Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data J. Clin. Oncol. 19, 851-856 (2001).
19. Kabbinavar F, Hurwitz H, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21(1), 60-65 (2003).
20. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
21. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer. 7(6), 475-485 (2007).
22. Dickler MN, Ragupathi G, Liu NX et al. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Clin. Cancer Res. 5(10), 2773-2779 (1999).
23. Bizzini B, Achour A. "Kinoids": the basis for anticytokine immunization and their use in HIV infection. Nat. Rev. Cancer (Noisy-le-grand). 41(3), 351-356 (1995).
24. Wei YQ, Wang QR, Zhao X et al. Immunotherapy of tumors with xenogeneic endothelial Cells as a vaccine. Nat. Med. 6, 1160-1166 (2000).
25. Okaji Y, Tsuno NH, Kitayama J et al. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci. 95, 85-90 (2004). • Use of autologous endothelial cells as an active vaccination strategy to induce antitumor response.
26. Li Y, Wang MN, Li H, King et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med. 195, 1575-1584 (2002). • Describes the use of flk1-pulsed dendritic in active immunization to inhibit tumor angiogenesis and metastasis.
27. Niethammer AG, Xiang R, Becker JC et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 8, 1369-1375 (2002). • Describes the use of a novel VEGF receptor-2 oral DNA vaccine to break immune tolerance and effectively inhibit tumor growth in mice.